Abstract:This study presents a biomimetic autophagosome‐based (BAPs) personalized nanovaccine that integrates neoantigens sourced from tumor cell‐derived autophagosomes, immunoadjuvants, and targeting nanovesicles to induce a potent tumor‐specific immune response. The BAPs nanovaccine demonstrates significant efficacy in eradicating established tumors, providing comprehensive protection to mice against tumor rechallenges, and decreasing tumor incidence. This represents a highly versatile formulation for personalized cancer immunotherapy. Personalized cancer vaccines based on tumor cell lysates offer promise for cancer immunotherapy yet fail to elicit a robust therapeutic effect due to the weak immunogenicity of tumor antigens. Autophagosomes, obtained from pleural effusions and ascites of cancer patients, have been identified as abundant reservoirs of tumor neoantigens that exhibit heightened immunogenicity. However, their potential as personalized cancer vaccines have been constrained by suboptimal lymphatic‐targeting performances and challenges in antigen‐presenting cell endocytosis. Here,a reinforced biomimetic autophagosome‐based (BAPs) nanovaccine generated by precisely amalgamating autophagosome‐derived neoantigens and two types of adjuvants capable of targeting lymph nodes is developed to potently elicit antitumor immunity. The redox‐responsive BAPs facilitate cytosolic vaccine opening within antigen‐presenting cells, thereby exposing adjuvants and antigens to stimulate a strong immune response. BAPs evoke broad‐spectrum T‐cell responses, culminating in the effective eradication of 71.4% of established tumors. Notably, BAPs vaccination triggers enduring T‐cell responses that confer robust protection, with 100% of mice shielded against tumor rechallenge and a significant reduction in tumor incidence by 87.5%. Furthermore, BAPs synergize with checkpoint blockade therapy to inhibit tumor growth in the poorly immunogenic breast cancer model. The biomimetic approach presents a powerful nanovaccine formula with high versatility for personalized cancer immunotherapy.

Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

A Novel Approach for Cancer Immunotherapy: Tumor Cells with Anchored Superantigen SEA Generate Effective Antitumor Immunity

Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells

Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect.

Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity

An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria

Entirely Synthetic Bacterial Nanomimics for Highly-Effective Tumor Suppression and Immune Elicitation

Harnessing Bacterial Membrane Components for Tumor Vaccines: Strategies and Perspectives

Phytochemical Engineered Bacterial Outer Membrane Vesicles for Photodynamic Effects Promoted Immunotherapy.

Bifunctional Fusion Membrane‐Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic Cells

Programmed Nanocloak of Commensal Bacteria-Derived Nanovesicles Amplify Strong Immunoreactivity against Tumor Growth and Metastatic Progression

Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity

Anti‐Tumor Immunity Induced by a Ternary Membrane System Derived From Cancer Cells, Dendritic Cells, and Bacteria (Small 50/2023)

Reconciling the Cooperative-Competitive Patterns among Tumor and Immune Cells for Triple-Negative Breast Cancer Treatment Using Multimodule Nanocomplexes

Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens

A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity

Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger

Nanocarriers based on bacterial membrane materials for cancer vaccine delivery

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy